Ortho RTI updates on clinical hold for drug trial

Biologics

Ortho Regenerative Technologies has submitted requested data related to its Ortho-R drug to the FDA after the company paused its clinical trial.

Ortho RTI shared additional chemistry, manufacturing and control information to the FDA, according to a July 20 news release.

The data is a response to a clinical hold letter the FDA sent Ortho RTI in June regarding Ortho-R, a biologic drug. Ortho-R received classification as a biologic drug last year.

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


You can unsubscribe from these communications at any time. For more information, please review our Privacy Policy.
 

Articles We Think You'll Like